Literature DB >> 6664243

Analgesic potentiation and the distribution of morphine in the presence of triplennamine in mice.

R E Bluhm, M A Evans, E K Zsigmond.   

Abstract

Interest in the interaction of opioids and histamine antagonists arose from the observation that abusers of pentazocine and triplennamine experience a heroin-like euphoria that neither drug alone produces. The present study was conducted to evaluate the analgesic properties of the combination of the histamine antagonist, triplennamine (TRP), and morphine (MS). Analgesia was assessed using the hot plate at 55 degrees C and all drugs were administered intravenously. TRP had no analgesic effect. When a suboptimal dose of MS (3.5 mg/kg) was combined with TRP in a dosage range of 2.5-5 mg/kg, the latency in response to pain 10 minutes after drug administration was significantly increased and this potentiation was still evident 30 minutes after drug administration. Naloxone completely reversed the analgesia of MS and the MS-TRP combination. The distribution of 3H morphine in representative brain areas and plasma was not different in the presence or absence of triplennamine.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6664243     DOI: 10.1016/0024-3205(83)90592-1

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

1.  Antihistaminics enhance morphine-, but not amphetamine- and scopolamine-induced hyperactivity in mice.

Authors:  M Sansone; B D'Udine; P Renzi; J Vetulani
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

2.  Tripelennamine enhances buprenorphine-, but not pentazocine-induced hyperactivity in mice.

Authors:  M Sansone; C Castellano; V Libri
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

3.  Effects of antihistaminics on naloxone-induced withdrawal in morphine-dependent mice.

Authors:  J C Leza; I Lizasoain; P Lorenzo
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.